成人癫痫手术后抗癫痫药物撤药时机的多中心观察研究
该多中心观察性队列纳入964例1990至2016年间接受切除性癫痫手术且撤药前无发作的成人,比较术后不同时间点启动ASM撤药的复发风险。倾向评分匹配后,术后第1年(HR 1.4;p=0.003)或第2年(HR 1.18;p<0.001)启动撤药者复发风险高于更晚撤药者,第3、4、5年启动未见风险增加;长期结局与撤药时机无显著关联。
要点
- 术后2年内启动ASM撤药与更高的初始癫痫复发风险相关。
- 术后第3、4、5年启动撤药未显示复发风险增加。
- 撤药时机与长期无发作及完全停用ASM的结局无显著关联。
核心结论
- 术后2年内启动ASM撤药与更高的初始复发风险相关,但长期结局与撤药时机无显著关联。
- 等待超过2年并未在降低癫痫风险方面带来额外获益。
研究设计与样本
- 多中心观察性队列研究,纳入1990至2016年间在12家三级中心接受切除性癫痫手术的成人。
- 共964例,51%为女性,手术时中位年龄34岁(四分位距26-44)。
- 纳入者撤药前无发作且随访至少1年。
- 比较术后第1、2、3、4、5年启动撤药与更晚撤药者的复发风险,采用倾向评分匹配调整治疗选择偏倚。
主要发现
- 446例(46%)在术后第1年启动ASM撤药,255例(26%)第2年,110例(11%)第3年,58例(6%)第4年,29例(3%)第5年,66例(7%)第5年后。
- 匹配后,第1年启动撤药者复发风险高于更晚撤药者(HR 1.4;p=0.003)。
- 第2年启动撤药者复发风险亦高于更晚撤药者(HR 1.18;p<0.001)。
- 第3年(HR 1.7;p=0.12)、第4年(HR 1.3;p=0.45)、第5年(HR 0.17;p=0.82)启动撤药与更晚撤药相比未见风险增加。
- 长期结局如最终随访时无发作及完全停用ASM与撤药时机无显著关联。
关键数值与推荐
- 术后第1年启动ASM撤药:复发风险HR 1.4(p=0.003)。
- 术后第2年启动ASM撤药:复发风险HR 1.18(p<0.001)。
- 术后第3年启动ASM撤药:HR 1.7(p=0.12)。
- 术后第4年启动ASM撤药:HR 1.3(p=0.45)。
- 术后第5年启动ASM撤药:HR 0.17(p=0.82)。
临床怎么用
- 撤药决策需由患者、照护者与临床医生共同参与,权衡偏好、受伤风险、社会因素(如驾驶、工作、监护)及临床判断。
- 应向患者透明告知撤药的风险与获益。
- 研究结果可为未来基于证据的撤药方案和随访策略提供真实世界依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: More than half of people undergoing epilepsy surgery become seizure-free and may consider withdrawing antiseizure medications (ASMs). Withdrawal practices vary, and the optimal timing remains unclear. We aim to compare seizure relapse risk among individuals initiating ASM withdrawal at different time points after epilepsy surgery. METHODS: We conducted a multicenter observational cohort study of adults who underwent resective epilepsy surgery between 1990 and 2016 at 12 tertiary centers. Participants were seizure-free before medication withdrawal and had at least 1 year of follow-up. Seizure relapse risk was compared among those initiating withdrawal 1, 2, 3, 4, or 5 years postoperatively vs later. We used propensity score matching for each comparison to adjust for treatment selection bias. RESULTS: Of the 964 people included (51% female; median age at surgery 34 years [interquartile range 26-44]), 446 (46%) began ASM withdrawal in the first year after surgery, 255 (26%) in the second, 110 (11%) in the third, 58 (6%) in the fourth, 29 (3%) in the fifth, and 66 (7%) after the fifth year. After matching, those starting withdrawal in the first (hazard ratio [HR] 1.4; p = 0.003) or second (HR 1.18; p < 0.001) year had a higher risk of relapse than those who withdrew later. Starting withdrawal in the third (HR 1.7; p = 0.12), fourth (HR 1.3; p = 0.45), or fifth (HR 0.17; p = 0.82) year after surgery showed no increase in risk compared with later withdrawal. Long-term outcomes, such as seizure freedom and being entirely off ASMs at the final follow-up, were not substantially associated with withdrawal timing. DISCUSSION: Initiating ASM withdrawal within the first 2 postoperative years was linked to a higher initial risk of seizure relapse compared with later withdrawal, although long-term outcomes were similar regardless of withdrawal timing. Waiting more than 2 years did not confer additional benefit in reducing seizure risk. Deciding whether and when to withdraw ASMs is a shared process involving individuals, caregivers, and clinicians, balancing preferences, risk of injury, social factors (e.g., driving, work, and supervision), and clinical judgment. Transparent information on risks and benefits is essential. Our findings offer real-world evidence that may inform future evidence-based withdrawal protocols and follow-up strategies.
引用
- Ferreira-Atuesta C, De Tisi J, Mcevoy AW, et al. Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults. Neurology. 2026. PMID: 41592265. doi:10.1212/WNL.0000000000214613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。